Psoriasis
📧 Sign up to get email alerts when something new happens for Psoriasis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Hulio (adalimumab) biosimilar with approvals across multiple inflammatory indications.
-
EMA approval · 2026-08-26EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
Regulatory authorization for Skyrizi (risankizumab) by AbbVie Deutschland GmbH & Co. KG across multiple inflammatory diseases.
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-21EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited
EMA authorised Taltz (ixekizumab) for multiple indications including psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile a…
-
EMA approval · 2026-08-18EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-18EMA Authorised: Stelara (ustekinumab) — Janssen-Cilag International NV
EU authorises Stelara (ustekinumab) for multiple indications including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colit…
-
EMA approval · 2026-08-11EMA Authorised: Usgena (ustekinumab) — Stada Arzneimittel AG
Stada Arzneimittel AG authorized to market Usgena (ustekinumab) for Crohn's disease, psoriasis, psoriatic arthritis, and ulcerative colitis …
-
EMA approval · 2026-08-11EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited
Yesintek (ustekinumab) from Biosimilar Collaborations Ireland Limited has been authorised by the EMA for psoriasis, psoriatic arthritis, and…
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA approval · 2026-07-30EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
Biosimilar adalimumab (Hulio) has been authorised by EMA for multiple indications including hidradenitis suppurativa, psoriasis, uveitis, rh…
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
EMA approval · 2026-07-01EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC
Authorised approval of Wezenla (ustekinumab) by EMA for psoriasis, psoriatic arthritis, and Crohn's disease.
-
EMA approval · 2026-07-01EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
Authorised status for Erelzi (etanercept) by Sandoz GmbH, expanding access to therapy for multiple inflammatory arthritis conditions.
-
EMA approval · 2026-06-25EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
EU authorisation of Skyrizi (risankizumab) for multiple inflammatory diseases including psoriasis, psoriatic arthritis, ulcerative colitis, …
-
EMA approval · 2026-06-12EMA Authorised: Fubelv — Biosimilar Collaborations Ireland Limited
EMA has authorised Fubelv as a biosimilar, with indications across various inflammatory arthritis and psoriasis conditions.
-
EMA approval · 2026-06-12EMA Authorised: Apremilast Accord — Accord Healthcare S.L.U.
Accord Healthcare S.L.U. has been authorised in the EU for apremilast (Accord).
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
-
EMA approval · 2026-06-03EMA Authorised: Sotyktu (deucravacitinib) — Bristol-Myers Squibb Pharma EEIG
EMEA authorises Sotyktu (deucravacitinib) for its indication in psoriasis, marking a new approved therapy in the EU.
-
EMA approval · 2026-04-24EMA Authorised: Stelara (ustekinumab) — Janssen-Cilag International NV
The EMA has authorised Stelara (ustekinumab) in the EU for psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
-
EMA approval · 2026-04-23EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited
EMA authorised Taltz (ixekizumab) from Eli Lilly for psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthri…
-
EMA approval · 2026-04-23EMA Authorised: Remsima (infliximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Remsima (infliximab) from Celltrion Healthcare Hungary Kft. for multiple inflammatory diseases including rheumatoid arthritis…
-
EMA approval · 2026-04-23EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheu…